These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 28532400)

  • 21. Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer : An investigation of 117 pelvic lymph nodes.
    Cozzi S; Botti A; Timon G; Blandino G; Najafi M; Manicone M; Bardoscia L; Ruggieri MP; Ciammella P; Iotti C
    Strahlenther Onkol; 2022 Aug; 198(8):700-709. PubMed ID: 34757443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer.
    Rogowski P; Trapp C; von Bestenbostel R; Schmidt-Hegemann NS; Shi R; Ilhan H; Kretschmer A; Stief C; Ganswindt U; Belka C; Li M
    Radiat Oncol; 2021 Jun; 16(1):125. PubMed ID: 34193194
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy.
    Henkenberens C; Oehus AK; Derlin T; Bengel F; Ross TL; Kuczyk MA; Janssen S; Christiansen H; von Klot CAJ
    Strahlenther Onkol; 2020 Nov; 196(11):1006-1017. PubMed ID: 32399639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment outcomes of metastasis-directed treatment using
    Hurmuz P; Onal C; Ozyigit G; Igdem S; Atalar B; Sayan H; Akgun Z; Kurt M; Ozkok HB; Selek U; Oymak E; Tilki B; Guler OC; Mustafayev TZ; Saricanbaz I; Rzazade R; Akyol F
    Strahlenther Onkol; 2020 Nov; 196(11):1034-1043. PubMed ID: 32617620
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial.
    Siva S; Bressel M; Murphy DG; Shaw M; Chander S; Violet J; Tai KH; Udovicich C; Lim A; Selbie L; Hofman MS; Kron T; Moon D; Goad J; Lawrentschuk N; Foroudi F
    Eur Urol; 2018 Oct; 74(4):455-462. PubMed ID: 30227924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis.
    Ost P; Jereczek-Fossa BA; As NV; Zilli T; Muacevic A; Olivier K; Henderson D; Casamassima F; Orecchia R; Surgo A; Brown L; Tree A; Miralbell R; De Meerleer G
    Eur Urol; 2016 Jan; 69(1):9-12. PubMed ID: 26189689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience.
    Ingrosso G; Trippa F; Maranzano E; Carosi A; Ponti E; Arcidiacono F; Draghini L; Di Murro L; Lancia A; Santoni R
    World J Urol; 2017 Jan; 35(1):45-49. PubMed ID: 27233779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CyberKnife stereotactic radiosurgery and stereotactic ablative radiation therapy of patients with prostate cancer bone metastases.
    Napieralska A; Miszczyk L; Stapor-Fudzinska M
    Neoplasma; 2016; 63(2):304-12. PubMed ID: 26774153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy.
    Ponti E; Lancia A; Ost P; Trippa F; Triggiani L; Detti B; Ingrosso G
    Eur Urol Focus; 2017 Dec; 3(6):538-544. PubMed ID: 28801240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer.
    Franzese C; Zucali PA; Di Brina L; D'Agostino G; Navarria P; Franceschini D; Santoro A; Scorsetti M
    Cancer Med; 2018 Sep; 7(9):4379-4386. PubMed ID: 30073758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. "Give me five" ultra-hypofractionated radiotherapy for localized prostate cancer: non-invasive ablative approach.
    Marvaso G; Riva G; Ciardo D; Gandini S; Fodor C; Zerini D; Colangione SP; Timon G; Comi S; Cambria R; Cattani F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
    Med Oncol; 2018 May; 35(6):96. PubMed ID: 29748830
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy.
    Bolzicco G; Favretto MS; Satariano N; Scremin E; Tambone C; Tasca A
    BMC Urol; 2013 Oct; 13():49. PubMed ID: 24134138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy.
    Nicosia L; Cuccia F; Mazzola R; Ricchetti F; Figlia V; Giaj-Levra N; Rigo M; Tomasini D; Pasinetti N; Corradini S; Ruggieri R; Alongi F
    Strahlenther Onkol; 2020 Sep; 196(9):813-820. PubMed ID: 32399637
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer.
    Mohan R; Kneebone A; Eade T; Hsiao E; Emmett L; Brown C; Hunter J; Hruby G
    Radiat Oncol; 2023 Aug; 18(1):127. PubMed ID: 37528487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Linac-based stereotactic salvage reirradiation for intraprostatic prostate cancer recurrence: toxicity and outcomes.
    Cozzi S; Finocchi Ghersi S; Bardoscia L; Najafi M; Blandino G; Alì E; Augugliaro M; Vigo F; Ruggieri MP; Cardano R; Giaccherini L; Iori F; Botti A; Trojani V; Ciammella P; Iotti C
    Strahlenther Onkol; 2023 Jun; 199(6):554-564. PubMed ID: 36732443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy.
    Mbeutcha A; Chauveinc L; Bondiau PY; Chand ME; Durand M; Chevallier D; Amiel J; Kee DL; Hannoun-Lévi JM
    Radiat Oncol; 2017 Mar; 12(1):49. PubMed ID: 28274241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study.
    Triggiani L; Alongi F; Buglione M; Detti B; Santoni R; Bruni A; Maranzano E; Lohr F; D'Angelillo R; Magli A; Bonetta A; Mazzola R; Pasinetti N; Francolini G; Ingrosso G; Trippa F; Fersino S; Borghetti P; Ghirardelli P; Magrini SM
    Br J Cancer; 2017 Jun; 116(12):1520-1525. PubMed ID: 28449007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study.
    Mazzola R; Fersino S; Ferrera G; Targher G; Figlia V; Triggiani L; Pasinetti N; Lo Casto A; Ruggieri R; Magrini SM; Alongi F
    Med Oncol; 2018 Aug; 35(9):121. PubMed ID: 30076479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost and whole pelvic radiotherapy for intermediate- and high-risk prostate cancer.
    Kim HJ; Phak JH; Kim WC
    Asia Pac J Clin Oncol; 2017 Feb; 13(1):21-27. PubMed ID: 26969216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.